Major Areas of Research
- Mechanisms of HIV persistence in vivo
- Genetic and gene expression analyses of viruses and host cells
The goal of the VPDS is to help develop means of targeting virus reservoirs and reducing disease progression in people living with HIV. One path toward this goal is to clarify the fundamental biology of HIV persistence during antiretroviral therapy (ART). Motivated by the genetic and functional diversity within key cellular reservoirs for the virus, we are developing high-throughput methods for characterizing large numbers of single cells and viruses in great detail. Topics under investigation include the unique genetic programs expressed by infected cells; heterogeneity among individual infected cells as measured using “omics” tools; and the use of virus genetic analysis to detect critical events that may not be directly observable in vivo. We are investigating these issues both in individuals treated with standard-of-care ART and in study participants receiving experimental HIV cure-directed therapies.
Dr. Boritz began his HIV research career in the mid-1990s as a summer student in the laboratory of Dr. John K. Rose. An interest in fundamental and translational studies of host-virus interactions then led him to pursue combined M.D./Ph.D. training at University of Colorado Health Sciences Center in Denver. He completed his Ph.D. in the Immunology Program studying HIV-specific CD4 T-cell responses with Dr. Cara Wilson. After an internship and residency in Internal Medicine at Johns Hopkins Hospital, he came to NIAID as a fellow in infectious diseases. Following the clinical portion of his fellowship, he joined Dr. Daniel Douek's laboratory at Vaccine Research Center, where he worked to understand the cellular and molecular events that allow HIV reservoirs to persist in vivo. He joined the NIH faculty to establish the VPDS in 2017.
B.S., Cellular & Molecular Biology – University of Puerto Rico
M.S., Bioinformatics – Johns Hopkins University
Ph.D., Microbial Technology – Amity University
M.S., Biotechnology – Jamia Hamdard University
Sung Hee Ko
Ph.D., Mechanical Engineering – Pohang University of Science & Technology
M.S., Mechanical Engineering – Pohang University of Science & Technology
B.S., Mechanical Engineering – Pusan National University
Si Young Lee
Ph.D., Molecular Biology – Seoul National University
M.S., Molecular Biology – Seoul National University
B.S., Biology – Sungkyunkwan University
Ph.D., Physiology & Integrative Biology – UMDNJ/Rutgers University
B.S., Biology – University of Puerto Rico
B.S., Chemical & Biological Engineering – University of Colorado at Boulder
Pérez L, Anderson J, Chipman J, Thorkelson A, Chun TW, Moir S, Haase AT, Douek DC, Schacker TW, and Boritz EA. Conflicting evidence for HIV enrichment in CD32+ CD4 T cells. Nature. 20 Sep 2018; 561, E9-E16.
Boritz EA, Darko S, Swaszek L, Wolf G, Wells D, Wu X, Henry AR, Laboune F, Hu J, Ambrozak D, Hughes MS, Hoh R, Casazza JP, Vostal A, Bunis D, Nganou-Makamdop K, Lee JS, Migueles SA, Koup RA, Connors M, Moir S, Schacker T, Maldarelli F, Hughes SH, Deeks SG, and Douek DC. Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell. 20 July 2016; pii: S0092-8674(16)30810-8.
Petrovas C, Ferrando-Martinez S, Gerner M, Pegu A, Deleage C, Ambrozak A, Del Río-Estrada P, Paris R, Boswell K, Ruiz-Mateos E, Boritz E, Giannikaki E, Leal M, Ablanedo-Terrazas Y, Rivero A, Gonzalez-Hernandez LA, Reyes-Teran G, Docobo F, Pantaleo G, Douek DC, Betts MR, Estes JD, Germain R, Mascola J and Koup RA. Follicular CD8 T cells accumulate in HIV and kill infected cells in vitro via bispecific antibodies. Sci Transl Med. 18 Jan 2017; 9(373). pii: eaag2285.
Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O’Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE; VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 23 Dec 2015; 7(319):319ra206.
Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB Jr, Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, and Douek DC. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014 Jul 31;511(7511):601-5.
Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price TW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, and Deeks SG. 2013. Challenges in Detecting HIV Persistence during Potentially Curative Interventions: a Study of the Berlin Patient. PLoS Pathogens. 2013 May;9(5):e1003347.